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Abstract
Background: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK
(Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/
bladder-cancer, Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy
for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of
localised muscle invasive bladder cancer. However, cisplatin resistance remains a critical cause of treatment failure and
a barrier to therapeutic advance in UBC. Based on supportive pre-clinical data, we hypothesised that DNA
methyltransferase inhibition would circumvent cisplatin resistance in UBC and potentially other cancers.
Methods: The addition of SGI-110 (guadecitabine, a DNA methyltransferase inhibitor) to conventional doublet therapy
of gemcitabine and cisplatin (GC) is being tested within the phase Ib/IIa SPIRE clinical trial. SPIRE incorporates an initial,
modified rolling six-dose escalation phase Ib design of up to 36 patients with advanced solid tumours followed by a
20-patient open-label randomised controlled dose expansion phase IIa component as neoadjuvant treatment for UBC.
Patients are being recruited from UK secondary care sites. The dose escalation phase will determine a recommended
phase II dose (RP2D, primary endpoint) of SGI-110, by subcutaneous injection, on days 1–5 for combination with GC at
conventional doses (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15) in
every 21-day cycle. In the dose expansion phase, patients will be randomised 1:1 to GC with or without SGI-110 at the
proposed RP2D. Secondary endpoints will include toxicity profiles, SGI-110 pharmacokinetics and pharmacodynamic
biomarkers, and pathological complete response rates in the dose expansion phase. Analyses will not be powered for
formal statistical comparisons and descriptive statistics will be used to describe rates of toxicity, efficacy and
translational endpoints by treatment arm.
Discussion: SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and
biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers
treated with GC.
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Background
Urothelial bladder cancer (UBC) accounts for 10,000 new
diagnoses and 5000 deaths annually in the UK [1].
Cisplatin-based chemotherapy is a standard of care ther-
apy for UBC in both the palliative first-line setting of ad-
vanced/metastatic disease and for radical neoadjuvant
treatment of localised muscle invasive bladder cancer
(MIBC) [2–4]. Globally, the most common regimen is ei-
ther a doublet combination with gemcitabine (GC) or in
combination with methotrexate, vinblastine and doxorubi-
cin [4, 5]. Attempts to replace cisplatin as a component of
chemotherapy regimens, for example, with carboplatin,
have been unsuccessful in terms of reduced efficacy in
UBC [5]. For metastatic disease, GC results in a median
survival and time to progressive disease of approximately
14 and 7 months, respectively. Cisplatin-based neoadju-
vant chemotherapy, prior to either radical cystectomy or
radical radiotherapy for MIBC, adds an absolute sur-
vival advantage of 5–6% to overall cure rates, aver-
aged across T stages at approximately 50% [2, 3, 6].
Cisplatin resistance remains a critical barrier to thera-
peutic advance in UBC. For example, in a key rando-
mised trial comparing cisplatin-based regimens for
advanced disease, 17% of patients had primary refractory
disease and, by 3 years, only 13% were alive and free
from progression [7]. Progression or relapse of UBC fol-
lowing cisplatin-based chemotherapy is associated with a
dismal prognosis. For patients receiving second-line pal-
liative chemotherapy or immunotherapy, after a prior
platinum-based regimen, the median survival is consist-
ently under 1 year with a median progression-free sur-
vival in the range of 2 to 5 months [5]. Recent data for
second line use of palliative immunotherapy with the
programmed cell death protein 1 inhibitor pembrolizu-
mab has established a modest improvement in median
overall survival of 10.3 months for the pembrolizumab
group compared to 7.4 months in the chemotherapy
arm [8]. To date, no biomarker-directed stratified treat-
ment strategy has been established for use in UBC [5].
Taken as a whole, the data available for MIBC and meta-
static UBC outcomes imply a pressing unmet need for
improvements to what is currently achieved with sys-
temic therapy.
Altered gene expression in cancer may arise through
structural genomic changes, such as gene mutation or
loss/gain of chromosomal content, or through reversible
changes in the regulation and expression of genes. The
latter, known as epigenetic control, includes biochemical
modifications to the histone proteins adjacent to chro-
matin, and to DNA itself [9]. To date, DNA methylation
at CpG di-nucleotides is the best studied epigenetic
change in cancer. In general, there is a dysregulation of
CpG methylation in cancerous cells that can lead to gen-
omic instability and activation of previously silent onco-
genes or silencing of tumour suppressor genes. In UBC,
many genes are affected by promoter hypermethylation
[10]. Reversal of this hypermethylation through DNA
methyltransferase inhibition, or siRNA approaches, al-
lows tumour suppressor gene re-expression and there-
fore holds promise as a potential anti-cancer therapy.
Pre-clinical data from a variety of sources has shown
that a strategy to combine a DNA demethylating agent
with platinum-based chemotherapy might improve on
current outcomes for UBC. These data indicate that, in
addition to single agent activity, demethylating agents
synergise with cisplatin and are able to circumvent cis-
platin resistance in experimental models [11–16]. Data
also exist to support investigation of a DNA hypomethy-
lating agent with gemcitabine [17–21].
SGI-110 (guadecitabine, Astex Pharmaceuticals) is a
DNA methyltransferase inhibitor composed of a di-
nucleotide of decitabine and deoxyguanosine formulated
for subcutaneous injection. SGI-110 is in clinical devel-
opment for a range of haematological and solid malig-
nancies and is currently under investigation in phase I to
III clinical trials. In a first in human phase I study, a
maximum tolerated dose (MTD) was established at 90
mg/m2 daily × 5 in patients with myelodysplastic
syndrome but was not reached in patients with acute
myeloid leukaemia [22]. DNA demethylation was found
to reach a plateau at 60 mg/m2 and this was designated
as the biologically effective dose and recommended for
phase II development. The most frequent grade 3 or
higher adverse events were febrile neutropenia,
pneumonia, thrombocytopenia, anaemia, and sepsis.
Clinical responses to treatment were seen in some
patients and confirmed in a subsequent phase II trial
leading to an ongoing phase III study in acute myeloid
leukaemia [23].
Decitabine and guadecitabine have been successfully
combined with carboplatin with acceptable toxicity, epi-
genetic re-sensitisation and suggestion of a clinical
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benefit in heavily pre-treated ovarian cancer patients
[24] (Matulonis UA, Oza A, Alvarez-Secord A, et al., un-
published observations). We hypothesise that cisplatin
resistance might be reversed or avoided through co-
administration with a DNA hypomethylating agent such
as SGI-110.
Methods/Design
The SPIRE trial is a phase Ib/IIa trial evaluating whether
SGI-110 in combination with GC chemotherapy is safe
and has a biologically effective dose.
Objectives
The primary objective is to determine a recommended
phase II dose (RP2D) for future phase II/III investigation
as a neoadjuvant therapy in UBC. Furthermore, SPIRE
aims to establish a RP2D for SGI-110 when combined
with GC chemotherapy from both the MTD based on
defined criteria for dose limiting toxicity (DLT) assessed
by Common Terminology Criteria for Adverse Events
(CTCAE) v4.03 and the maximally biologically effective
dose (MBED) based on plasma/serum DNA LINE-1
methylation and haemoglobin F (HbF) re-expression sta-
tus [25–27].
Secondary objectives include the evaluation of toxicity,
assessed using CTCAE v4.03 at baseline, at each treat-
ment cycle and at each follow-up visit; treatment com-
pliance, assessed using electronic case report forms
(eCRFs) during the treatment period; and pathological
complete response rate (of bladder cancer patients en-
rolled in the phase IIa part of the trial).
Translational objectives include the evaluation of phar-
macokinetic and pharmacodynamic effects of SGI-110
when combined with GC. Blood and bladder cancer tis-
sue samples will be used to investigate (including but
not limited to) promoter methylation of MAGE-A1 and
other cancer testis antigens and 5-methylcytosine levels
and biomarkers of Nrf2 activation, including Nrf2,
KEAP1 and Nrf2 transcriptional targets (e.g. glutathione
reductase-1, metallothioneins, NQO-1).
Study design
Phase Ib dose escalation component
An initial dose escalation phase Ib component of the
trial combines SGI-110 with GC chemotherapy in ad-
vanced solid tumours to establish a RP2D, using a modi-
fied rolling six-phase Ib design [28] (Fig. 1).
GC chemotherapy will be given for up to six cycles of a
21-day cycle. Cisplatin 70 mg/m2 will be administered on
day 8 of each cycle by IV infusion over 2–4 h and
gemcitabine 1000 mg/m2 on days 8 and 15 of each cycle
by IV infusion over 30–60 min (and prior to cisplatin on
day 8) (Table 1). Supportive treatment including anti-
emetics and a suitable intravenous hydration schedule
pre- and post-cisplatin will be administered according to
local institutional policy.
Four increasing dose levels of SGI-110 are planned
(Table 2, dose level −1 is for those patients in dose level
1 requiring a dose reduction for treatment related tox-
icity). No intra-patient dose escalation will be
undertaken.
SGI-110 administration will be by sub-cutaneous injec-
tion, preferably in the abdominal area. Within each dose
level cohort, 3–6 evaluable patients will be entered. A
period of 21 days from the first patient starting treatment
until treatment of subsequent patients will be observed.
Patients in initial dose level cohorts will not receive
granulocyte-colony stimulating factor (G-CSF) as pri-
mary prophylaxis. If a DLT occurs, specifically due to
neutropenia and/or its complications, then an additional
3–6 patients will be recruited to repeat the current dose
Fig. 1 Trial schema
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level cohort with G-CSF incorporated as primary
prophylaxis for all patients (e.g. filgrastim or local
equivalent incorporated at a dose of 300 μg subcutane-
ous injection daily for 7 days from day 15 of each cycle)
(Table 1). Subsequent cohorts will continue to use G-
CSF as primary prophylaxis for all patients.
Dose modifications will be made for patients that do
not meet certain haematological parameters on day of
treatment together with dose modification criteria for
non-haematological toxicities (Additional file 1 explains
these dose modifications in more detail).
A DLT is assessed by CTCAE v4.03 and defined as any of
the following events occurring between the first dose ad-
ministration of SGI-110 and day 1 of the second cycle of
treatment if related to the combination of SGI-110 and GC.
The events are (1) greater than 14 days of delay in com-
mencing a second cycle of treatment due to drug toxicity;
(2) grade 4 neutropenia ≥ 7 days duration; (3) grade 3–4
neutropenia associated with a body temperature ≥ 38.5 °C;
(4) grade 3–4 neutropenia associated with bacteriologically
proven sepsis; (5) any grade 4 thrombocytopenia ≥ 7 days
duration; (6) grade 3 thrombocytopenia associated with
non-traumatic bleeding; or (7) any other clinically signifi-
cant grade 3 or above toxicity except nausea or vomiting.
Criteria for dose escalation between patient cohorts,
and determination of MTD, are defined in Table 3.
The MBED will be based on plasma/serum DNA
LINE-1 demethylation and HbF re-expression at day 8 of
the chemotherapy cycle [22, 23, 29]. If a dose level is de-
fined beyond which no further increase in demethylation
of plasma/serum DNA LINE-1 or re-expression of HbF
is seen, then this will be defined as the MBED (if the
MBED is above the MTD then no further dose escal-
ation would occur and the MBED would remain un-
defined). Schedule may also be explored, in addition to
dose, to optimise hypomethylation based on plasma/
serum DNA LINE-1 methylation and HbF re-expression
status with respect to timing of cisplatin administration
based on emergent data.
The RP2D will be established using the MTD and
MBED according to the following principles: (1) if the
MBED is clearly demonstrated to be below the MTD,
then it will be utilised as the RP2D; (2) if the MBED and
MTD are established to be equivalent, then this would
be the RP2D; (3) if the MTD occurs at a dose at which
at least a degree of plasma/serum DNA LINE-1 demeth-
ylation and/or HbF re-expression occurs (but not neces-
sarily maximal), then the MTD would be used as the
RP2D; and (4) if the MTD occurs at a dose at which no
plasma/serum DNA LINE-1 demethylation or HbF re-
expression is demonstrated, then this would result in
discontinuation of development of this combination.
At least six evaluable patients are needed to determine
RP2D. An evaluable patient is defined as one that, during
cycle 1, has completed all relevant safety evaluation re-
quirements and has received full doses of SGI-110 on days
1–5 and received full doses of GC on day 8 and has re-
ceived at least one dose of G-CSF if the patient has been
registered to a cohort with G-CSF prophylaxis in use. An
evaluable patient is also a patient who has experienced a
DLT. Once the RP2D has been determined, six additional
patients will be recruited to assess the RP2D in patients
with incurable advanced/metastatic UBC.
Depending on the tolerability of SGI-110 when com-
bined with GC the number of patients recruited in the
dose escalation phase Ib component of the trial will
range from 3 to 36.
Phase IIa randomised component
If a suitable RP2D can be determined, the trial will
proceed to an open label, randomised dose expansion
phase IIa component in the neoadjuvant setting for UBC
to evaluate either GC chemotherapy alone or in
Table 1 Treatment schedule over 21-day cycle
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
SGI-110 X X X X X
Cisplatin X
Gemcitabine X X
(Granulocyte-colony stimulating factor)a (X) (X) (X) (X) (X) (X) (X)
aColony stimulating factor (G-CSF) administration: Patients in the initial dose level cohorts in the Dose Escalation Phase will not receive G-CSF as primary prophy-
laxis. If a patient in those initial cohorts is deemed to require G-CSF for a subsequent treatment cycle then they will discontinue SGI-110 and further use of cis-
platin/gemcitabine will be at the discretion of the local investigator.Subsequent dose level cohorts may have G-CSF incorporated as primary prophylaxis for all
patients according to the rules described under section 3.5. All subsequent patients will then have G-CSF (e.g. filgrastim or local equivalent) incorporated at a dose
of 300 μg SC daily for 7 days from day 15 of each cycle
Table 2 Dose cohort levels for the phase Ib dose escalation phase
Dose level SGI-110 dose, per treatment cycle
−1 10 mg/m2, daily, on days 1–5
1 20 mg/m2, daily, on days 1–5
2 30 mg/m2, daily, on days 1–5
3 45 mg/m2, daily, on days 1–5
4 60 mg/m2, daily, on days 1–5
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combination with the RP2D of SGI-110 identified in the
dose escalation phase (Fig. 1). GC chemotherapy alone is
considered routine standard treatment in the UK and,
according to local practice, patients will receive up to 3
to 4 cycles of treatment. Patients will be randomised by
clinic staff at site, 20 patients will be randomised using a
web-based system in a 1:1 ratio using the method of per-
muted blocks. Treatment allocation will be unblinded.
There will not be a formal statistical comparison be-
tween the two groups.
SPIRE will be run in three Experimental Cancer
Medicine Centres in the UK with the aim of recruiting
up to a total of 56 patients.
Ethical and regulatory aspects
SPIRE has received ethical approval by the North West-
Haydock Research Ethics Committee (15/NW/0936) and
has approval from the UK Medicines and Health Care
Product Regulatory Agency (MHRA). Southampton
Clinical Trials Unit (SCTU), a Cancer Research UK core
funded and UK Clinical Research Collaboration regis-
tered Clinical Trials Unit (CTU), is coordinating the
trial. A list of recruiting sites can be obtained from the
SCTU. University Hospital Southampton National
Health Service Foundation Trust is the sponsor for the
trial [30]. The SPIRE Trial Management Group (TMG)
includes representatives from oncology, PPI representa-
tion and CTU staff involved in the day-to-day running
of the trial. A SPIRE Safety Review Committee (SRC),
comprising of oncology clinicians, statisticians and CTU
staff, will review and assess safety, tolerability and any
available pharmacokinetic and pharmacodynamic data to
make protocol-defined decisions regarding trial progress
during the dose escalation phase, including a decision to
dose escalate or define the RP2D. The SRC will receive
and review information on the progress and data relating
to the trial and advise the TMG and Trial Steering Com-
mittee on the proposed conduct of the SPIRE trial dose
escalation phase. In addition, an independent Trial
Steering Committee is established, and a Data
Monitoring and Ethics Committee comprising two clini-
cians and a statistician experienced in this research area
will be constituted on the launch of the dose expansion
phase to monitor trial progress and safety. Charters for
these groups are available via spire@soton.ac.uk.
The SCTU has undertaken a risk assessment for the
SPIRE trial which includes the requirements for moni-
toring (both central and site). The SCTU undertakes a
number of internal audits of its own systems and pro-
cesses annually and has routine audits from both its
sponsor and the independent MHRA every 2–3 years.
The trial is registered on the UK NIHR trial portfolio,
meaning there are research nurses based at UK cancer
hospitals who help in screening potential patients to
identify those eligible for the trial.
Study participants
For the dose escalation phase I, the SPIRE trial is currently
recruiting patients with incurable histologically or cyto-
logically confirmed, locally advanced or metastatic, solid
cancer, for which the use of GC is a clinically appropriate
treatment in the view of the local principal investigator.
Any number of previous lines of systemic chemotherapy is
permitted. Within the dose expansion phase II component,
we will recruit patients with bladder cancer with a pure or
a predominant component of transitional cell carcinoma
and clinical stage T2-4a N0 M0 who are planned to com-
mence GC for 3 or 4 cycles with neoadjuvant (i.e. curative)
intent prior to a planned radical cystectomy. No other in-
vestigational medicinal products should be received whilst
on study and no live vaccines should be received during
treatment and for 4 weeks following the end of treatment.
In accordance with the cisplatin summary of product char-
acteristics, nephrotoxic and ototoxic drugs are contraindi-
cated during the course of the trial (see Fig. 2 and Table 4
for eligibility criteria).
Withdrawal criteria
Participants are free to withdraw consent from the study
at any time without providing a reason. A participant
could also withdraw from receiving study treatment but
Table 3 Criteria for dose escalation between patient cohorts and determination of maximum tolerated dose (MTD)
Cohort size (evaluable patients) Dose limiting toxicities in cycle 1 Actions
3–6 0 Cohorts 1–3: dose escalation to the next cohort
Cohort 4: MTD is established at this dose level
< 6 1 Expand cohort to include up to 6 evaluable patients and re-evaluate
6 1 Cohorts 1–3: dose escalation to the next cohort
Cohort 4: MTD is established at this dose
≥ 2 ≥ 2 Dose level will be considered a non-tolerated dose; no further recruitment
to this cohort and dose escalation will cease
Cohort 1: The combination will be considered non-viable
(consider incorporation of granulocyte-colony stimulating factor G-CSF)
Cohorts 2–4: The previous dose level will be expanded to incorporate six
evaluable patients (consider incorporation of G-CSF)
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may not wish to withdraw from the trial. In this in-
stance, the participant will be encouraged to attend
follow-up visits in accordance with the trial schedule.
Should any participant become pregnant during the trial,
study treatment will be discontinued.
Study procedure
Recruitment and consent
Patients are approached within a hospital setting and
screened for eligibility by research staff to ensure all in-
clusion and exclusion criteria are met. Informed consent
to enter the trial is obtained from a patient by a clinician
only after a full explanation has been given, a patient in-
formation sheet provided and time allowed for consider-
ation. Patients may provide written consent up to 42
days prior to registration. Patients are also asked to con-
sent to provision of tumour and blood samples for use
in laboratory studies, including genetic analysis, and for
their data to be shared anonymously to support other re-
search in the future (Additional files 2 and 3).
Baseline visit
Following informed consent, assessments including a
physical examination, full blood count, serum biochem-
istry, including renal, liver and bone profiles, and glom-
erular filtration rate are completed within 28 days prior
to treatment commencing, with disease evaluation being
undertaken in accordance with local policy and routine
practice for the relevant disease site. Concomitant medi-
cations and medical history will be recorded. In addition,
women of child-bearing potential will undertake a preg-
nancy test. Following registration/randomisation bloods
and a formalin-fixed paraffin-embedded tumour tissue
block will be obtained, either archival or fresh if no
archival sample is available (see SPIRIT Figure, Figs. 2
and 3).
Treatment and follow-up visits
Participants attend hospital appointments for treatment
cycles with assessments as performed in the baseline
visit, plus adverse events, blood samples for translational
analyses, and pharmacokinetics and treatment compli-
ance. Following the treatment, phase participants enter a
post-treatment/progression follow-up to collect data on
adverse events, disease status and survival status. Serious
adverse event reporting occurs in real-time to the SCTU
safety desk throughout the study. Serious adverse events
are assessed to determine whether they are related to
drug treatment and unexpected or not, and subsequently
reported to both Astex Pharmaceuticals and the UK
regulatory bodies.
Data collection
Research staff at hospitals complete trial eCRFs via a re-
mote data collection tool (Medidata Rave). Data is
checked for missing or unusual values and checked for
consistency within participants over time by SCTU trial
staff. Any suspect data are raised as data queries. Site
staff respond to the queries providing an explanation/
resolution to the discrepancies. Full details on data man-
agement procedures are available in the SPIRE Data
Management Plan, available on request.
Source document verification and monitoring
The trial will be monitored and audited in accordance
with SCTU procedures. For the dose escalation phase,
all patients registered will trigger a monitor from SCTU
to visit site to source-verify data. This monitoring will
encompass comparing entries on the trial eCRF with
Fig. 2 SPIRIT figure for SPIRE phase Ib dose escalation component
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patients’ medical records and other supporting docu-
ments at site and documented in a monitoring report
form. Details will remain confidential, consistent with
data protection regulations. Drug accountability will also
be monitored throughout the trial. For the dose expan-
sion phase, the SCTU will use a risk-based monitoring
process to determine monitoring frequency and extent.
Statistical analysis
Dose escalation phase Ib
All patients entered into the phase Ib part of the trial will
be accounted for. The phase Ib analysis will focus on the
incidence of dose limiting toxicities, which will be sum-
marised by dose cohort. In addition, worst recorded tox-
icity grade for each patient on the National Cancer
Institute-CTCAE toxicity scale (version 4.03) during GC/
SGI-110 treatment will be summarised by dose cohort.
Details of dose delivery will also be summarised.
Dose expansion phase IIa
The analysis will be conducted in the intention-to-treat
population, which includes all randomisation patients
who have commenced study treatment. The analysis will
not be powered for formal statistical comparisons of effi-
cacy. Worst toxicity grade for each patient experienced
during chemotherapy will be summarised by treatment
arm and compared using the Mann–Whitney U test.
Relative dose intensity of GC will be summarised by
treatment arm. Pathological complete response rate ac-
cording to local assessment will be summarised by treat-
ment arm (the trial is not statistically powered for this).
A formal statistical analysis plan will be developed prior
to the end of the trial.
Interim analysis
A SRC will review the data during the phase Ib compo-
nent to determine dose escalation and RP2D. A Data
Monitoring and Ethics Committee will monitor the trial
during the phase IIa component where the safety, activ-
ity and treatment compliance analyses will be planned
and agreed with the Data Monitoring and Ethics Com-
mittee in advance. It is anticipated that all patients who
have been randomised will be included in these
analyses.
Table 4 Eligibility criteria for the SPIRE trial
Inclusion criteria
All patients
1. Eastern Cooperative Oncology Group performance status of 0 or 1
2. Glomerular filtration rate estimation of ≥ 60 mL/min according to
either the Cockcroft and Gault formula or by Cr-51 EDTA or Tc-99m
DTPA clearance
3. Adequate haematological parameters:
• Haemoglobin ≥ 90 g/L
• Neutrophil count ≥ 1.5 × 109/L
• Platelets ≥ 100 × 109/L
4. Adequate biochemical parameters:
• Bilirubin ≤ 1.5 × upper limit of normal (ULN)
• ALT and ALP ≤ 2.5 × ULN (ALP ≤ 5 × ULN if caused by liver
or bone metastases)
5. Aged 16 years or over
6. Life expectancy > 3 months
7. Provision of written informed consent
Patients in the dose escalation phase:
8. Incurable histologically or cytologically confirmed, locally advanced
or metastatic, solid cancer, for which the use of gemcitabine and
cisplatin is a clinically appropriate treatment in the view of the local
principal investigator; any number of previous lines of systemic
chemotherapy is permitted
Patients in the dose expansion phase:
9. Bladder cancer with a pure or predominant component of transitional
cell carcinoma
10. Clinical stage T2-4a N0 M0
11. Planned to commence GC for 3 or 4 cycles with neoadjuvant
(i.e. curative) intent prior to a planned radical cystectomy
Exclusion criteria
All patients
1. Unresolved toxicities from prior therapy greater than CTCAE v4.03
grade 1 (with the exception of alopecia) at the time of registration
2. Prior radiotherapy to > 30% of bone marrow
3. Major surgery within 30 days of registration/randomisation
4. Any investigational medicinal product within 30 days
registration/randomisation
5. Allergy or other known intolerance to any of the proposed study
drugs, including supportive agents and inclusive of G-CSF and locally
utilised anti-emetics
6. Previously identified central nervous system metastases unless treated
and clinically stable and not requiring steroids for at least 4 weeks
prior to the start of trial treatment
7. Coronary artery bypass graft, angioplasty, vascular stent, myocardial
infarction, unstable angina pectoris or congestive cardiac failure
(New York Heart Association ≥ class II) within the last 6 months
8. Women who are pregnant or breast feeding (women of child-bearing
potential must have a negative pregnancy test performed within
7 days prior to the start of trial treatment)
9. Patients of child-bearing potential who are not using a highly
effective method of contraception
10. Any patient who, in the judgment of the local investigator, is
unlikely to comply with trial procedures, restrictions or requirements
Table 4 Eligibility criteria for the SPIRE trial (Continued)
11. Any patient who has received a live vaccine within 4 weeks
of initiation of their treatment
Patients in the dose expansion phase:
12. Recent or current separate other malignancy; current non-melanoma
skin cancer, cervical carcinoma in situ or incidental localised prostate
cancer is permissible; participants with a history of a separate other
malignancy having completed all active treatment 2 or more years
previously may be entered
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All analyses will be carried out using STATA version
15 and SAS version 9 or later.
Adverse event reporting
Data on adverse events are collected at treatment and
follow-up visits. The trial also has a UK regulatory com-
pliant real-time serious adverse events reporting process
to identify serious adverse reactions and suspected unex-
pected serious adverse reactions that could suspend/stop
the trial if warranted.
End of the trial
The end of trial is defined as when the last patient has
had their last data collected.
Discussion
The outcome of this trial will provide evidence for
whether SGI-110 in combination with GC chemotherapy
is safe and a biologically effective dose to consider for fu-
ture phase II/III trials in the neoadjuvant bladder cancer
setting. The results may also be relevant for other cancers
where GC chemotherapy is utilised. Results will be dis-
seminated to patients and clinical teams through peer-
reviewed journal publications authored by the member of
the TMG and presented at international conferences.
Trial status
This clinical trial was registered in December 2015
(EudraCT Number: 2015–004062-29, and in February
2016 on ISRCTN registry number: 16332228). Re-
cruitment opened on May 5, 2016, and is expected to
be completed in December 2018. The current proto-
col is version 3, dated 08-Dec-16. REC/MHRA-ap-
proved protocol amendments will be communicated
to sites via email and updated trial documentation
provided centrally via the trial website. Trial registries
will be amended where relevant with explanations for
these changes.
Additional files
Additional file 1: Dose modification of SGI-110, gemcitabine and cis-
platin guidance. This guidance is used if the patient does not meet cer-
tain haematological parameters or non-haematological toxicities have
occurred. (PDF 107 kb)
Additional file 2: Copy of the consent form given to participants for
phase I dose escalation. (PDF 161 kb)
Additional file 3: Copy of the consent form given to participants for
phase II dose escalation. (PDF 161 kb)
Additional file 4: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT): a checklist for a set of scientific, ethical and
administrative elements recommended to be listed in a protocol [31].
(PDF 58 kb)
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